Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
Status:
Not yet recruiting
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously
unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV).
However, there is no specific anti-viral drug. It has been found that the specific antibodies
against virus antigen are produced after these patients were cured, which could block the
infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct,
rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the
study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate
the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the
treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment
of 2019-ncov pneumonia.